Investor Ideas #Potcasts 545, #Cannabis News and #Stocks on the Move; (OTCQB: $ALID) (OTC: $LRSV), (CSE: $RAMM.C) (OTC: $RAMMF), (TSX: $ZENA.TO)
Delta, Kelowna, BC, March 25, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/032521-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/03251ALID-LRSV-RAMM-ZENA.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public company announcements.
Allied Corp. (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues announced that it has successfully filed for trademark protection for its pharmaceutical product “PSILONEX.”
PSILONEX is a proprietary formulation prescribed within a treatment path that involves both
a pharmaceutical psilocybin-based formulation, followed by a daily cannabinoid maintenance period. PSILONEX is intended to be prescribed by a physician as “PSILONEX Rx,” followed by the cannabinoid daily therapy that can be purchased by the consumer in regions where it is legal to do so as “PSILONEX Daily,” Both of these products are currently being researched, developed and tested by Allied’s pharmaceutical development team.
The filed trademark protects Allied’s intellectual property for PSILONEX covering: chemical preparations for pharmaceutical or medical purposes, namely, for treating depression, anxiety, and PTSD, and for improving mental health; Nutraceuticals for the treatment of mental health disorders and conditions, including depression, anxiety, and PTSD; Nutraceuticals for use as a dietary supplement; Nutraceuticals for use as a dietary supplement for improving mental health; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of mental health disorders; Pharmaceuticals, namely, psychotropics; Dietary and nutritional supplements; Fungal extracts sold as a component ingredient of nutritional supplements and vitamins; Providing a website featuring information in the field of mental health and physical health, including living a healthy and disease-free life; Providing a website featuring information about health, wellness and nutrition; and Providing a website featuring information concerning alternative health and healing.
Link Reservations Inc. (OTC: LRSV), a provider of wellness and cannabidiol (CBD) products for both humans and pets, announced that the company is preparing to launch its first functional mushroom product, DailyLife CBD Immune. The new tincture product, tailored for people, will feature both CBD and a wide spectrum of functional mushrooms (including Lion's Mane) which help boost the immune system.
"This is an exciting first step for the Company and we are thrilled to soon bring to market our first CBD mushroom product. Our focus has always been on providing high quality products that can help people benefit from the power of natural ingredients, and that is what we have aimed for with this product," commented Rene Lauritsen, Link Reservations Inc CEO. "Understandably, people are focusing on their health now more than ever and looking for ways in which they can boost their immunity, particularly in a natural way. Our goal is to fully satisfy their need with this new product. We have been researching the benefits of functional mushrooms for the past few months and have developed a product that will harness their power," added Lauritsen.
As the world continues to reel from the Coronavirus pandemic, and learns to live with the virus, many people are focusing on different ways to boost their immune system. According to Rick Miller, Associate Director of Food & Drink Specialised Nutrition at Mintel, the majority of consumers in Europe purchase vitamins, minerals and supplements that strengthen the immune system, while in the US, 35% of consumers think products that support the immune health would motivate them when making a purchase.
DailyLife CBD Immune will feature an organic blend of 13 different medicinal mushrooms, including Lion's Mane, Turkey Tail, Chaga, Red Reishi and Cordyceps, amongst others. By focusing on a variety of mushrooms the product is able to encompass multiple immune boosting traits and benefits. In addition, DailyLife CBD Immune also includes 250mg of hemp oil CBD extract and 100mg of vitamin C, which will add to the immune boosting benefits.
"We are confident that this product and our future ones will have a very warm reception in the market, and we look forward to sharing more developments as they arise through press releases," ended Lauritsen.
For more information about DailyLifeCBD please visit: https://dailylifecbd.com/.
DailyLifeCBD is sister brand to LinkResPet, a website focused on providing CBD pet products for dogs, cats and horses. For more information about LinkResPet, please visit www.linkrespet.com or follow them on Twitter on @res_pet
RAMM Pharma Corp. (CSE: RAMM) (OTC: RAMMF), a leader in plant-derived cannabinoid pharmaceutical products, announced that it has initiated clinical trials studying the efficacy of its proprietary NettaVet™ pet cannabinoid formulation for the treatment of four pathologies in animals. The trials will be conducted in partnership with Universidad de la Republica de Uruguay in collaboration with leading international experts at Montreal University (Canada), University of Buenos Aires (Argentina), São Paulo State University (Brazil) and University of Barcelona (Spain). NettaLife is a wholly owned subsidiary of RAMM, dedicated to the production, export and commercialization of pet products, food, pharmaceutical specialties and cosmetic products for animals. More information can be found on NettaLife’s website www.nettalife.com.
The clinical trials will evaluate the efficacy of NettaVet™ cannabinoid formulations for the treatment of the following pathologies:
● Chronic Osteoarthritis pain in dogs (Cannis familiaris)
● Chronic Osteoarthritis pain in horses (Equus caballus)
● Allergic Dermatitis in dogs (Cannis familiaris)
● Anxiety in dogs (Cannis familiaris)
Prof. Dr. Nadia Crosignani, MSc., PhD (UdelaR, Uruguay), lead advisor for the clinical trials stated, “We are, from an academic stand point, very excited to be able to conduct these clinical trials together with RAMM Pharma and the prospects for these novel treatments to improve the quality life of animals.”
“We are pleased to commence this initial set of clinical trials with renowned experts to advance the development of products to help address some of the most common animal ailments,” stated Jack Burnett, Chief Executive Officer.
The NettaVet™ team is developing a line of specialized CBD veterinary and medicinal products for animals. CBD has shown benefits in animals including pain and inflammation reduction, immune system improvement, skin and fur care and cognitive support. NettaVet™ products will offer a natural, holistic medical alternative for animal care and which we believe may produce therapeutic results for diagnosed conditions such as Idiopathic epilepsy, canine lymphoma and anxiety, without the negative side effects of traditional veterinary medications. CBD is renowned as a very well-tolerated medication and nutraceutical that doesn't produce harmful side effects. In addition, CBD-based products are believed not to damage the kidneys, liver or gastrointestinal system. This business line will synergistically leverage RAMM’s pharmaceutical expertise to continue to further the development of its products which will begin being rolled out in 2021.
Zenabis Global Inc. (TSX: ZENA) announced the launch of pre-roll multipacks as well as new distribution agreements.
Zenabis' continues to expand on the popularity of its value-oriented Re-Up portfolio with the launch of its new 10 and 20, Multi-Pack Indica and Sativa 0.5g Pre-Roll formats. This unique, multi-pack will be available initally in Quebec and Alberta in the larger, 20-pack format in early April with national rollout of both formats expected to be in time for the 4/20 celebrations. The full impact of the launch is expected to be reflected in Zenabis's Q2 2021 results.
Zenabis' multipack pre-roll offering will serve consumers seeking better value for money and larger package sizes to reduce the frequency of purchases. These new products build on the success of Zenabis popular 28g Re-Up Indica / Sativa products. The launch of the 10 / 20 Multi-Pack Pre-Roll format underpins Zenabis strategy of leveraging its ability to deliver the quality and affordability expected by its loyal customer base while delivering on the top and bottom line performance anticipated by shareholders.
Zenabis is also excited to announce that it has concluded agreements with Cannabis NL (Newfoundland and Labrador) and the government of Nunavut, completing its goal of extending the availability of its Namaste and Re-Up products to all Canadian provinces and territories. Shipments under these new agreements commence in April. Zenabis joins a small, select group of Canadian LPs whose product quality and value have been recognized as a must-have, on-shelf product by every Provincial & Territorial Board in Canada. These new agreements further cement Zenabis as one of the top recreational LP's in the country.
"Finalizing agreements with Cannabis NL and the government of Nunavut, which means making good on our promise of making our Namaste and Re-Up brands available from coast-to-coast-to-coast, is a benchmark moment for this organization. We continue to portray what a lean, nimble company that grows really, really good cannabis can achieve. The addition of the pre-roll multipack to our assortment builds on Re-Up's brand purpose of providing affordable, high-THC products to our value-oriented customers" stated Robert Maxwell, Zenabis' Vice President, Sales and Marketing.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Play Music and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. LRSV is a frequent paid client for our news publishing service
Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
